Consider a long position in Hims & Hers Health (HIMS) while it trades in the low $20 range, as the stock currently suffers from a valuation disconnect despite resolving all major legal and regulatory risks. The company’s new partnership to distribute branded Wegovy and Ozempic at aggressive price points ($149–$299) serves as a massive revenue catalyst that is not yet reflected in official financial guidance. Novo Nordisk (NVO) has shifted from a legal adversary to a strategic partner, validating HIMS as a legitimate, high-volume distribution channel for the GLP-1 weight loss market. Investors should view the current volatility in growth stocks like HIMS and SoFi Technologies (SOFI) as a potential "buy the fear" opportunity where revenue has scaled significantly while share prices remain stagnant. This setup offers a high-conviction entry point for those who believe the market is incorrectly pricing the transition of telehealth into the mainstream pharmaceutical supply chain.

Hims & Hers Health, Inc. (HIMS)

The stock is currently experiencing significant volatility, trading in the low $20 range. Despite a broader market "crash" in growth stocks, the company has released several major positive updates regarding its GLP-1 (weight loss) product suite.

• Product Launches: Hims has officially launched branded GLP-1 solutions in partnership with Novo Nordisk.
  • Wegovy Pill: Launched at a price point of $149.
  • Wegovy Pen: Launched at $199.
  • Ozempic Pen: Available for $299 (focused on diabetes).
• Legal and Regulatory Resolution: The "Peak Fear" period from February 2026—which saw a DOJ referral, an FDA investigation, and a lawsuit from Novo Nordisk—has been fully resolved.
  • Novo Nordisk has dropped the lawsuit.
  • The DOJ and FDA investigations have concluded.
  • The company has transitioned from a legal adversary to an official partner of Novo Nordisk.
• Financial Performance:
  • Management recently reaffirmed their guidance and outlook during the Q1 earnings call.
  • Crucially, current financial guidance does not yet include the projected revenue from the newly launched branded GLP-1 products.
  • The speaker notes that the company’s revenue is significantly higher (nearly 10x) than it was five years ago, yet the stock price remains at similar levels.

Takeaways

• Valuation Disconnect: There is a perceived "complete nonsense" disconnect between the company's fundamental progress and its stock price. The stock is trading at the same levels seen during "Peak Fear," despite all major risks (lawsuits/investigations) being removed.
• Growth Catalyst: The launch of the Wegovy pill at $149 represents a major potential revenue driver that is not yet baked into the company's official financial guidance.
• Sentiment: The current bearish price action is attributed to a broader market breakdown in growth stocks rather than company-specific failures. This may present a "buy the fear" opportunity for investors who believe the market is incorrectly pricing the GLP-1 transition.

Novo Nordisk (NVO)

While the focus was on Hims, Novo Nordisk was highlighted as a key strategic partner rather than a competitor.

• Partnership Shift: Novo Nordisk has moved from suing Hims to using them as a distribution channel for branded products.
• Market Validation: The partnership and "congratulatory" tone from Novo leadership suggest that Hims has solidified its legitimacy in the telehealth space for high-demand weight loss drugs.

Takeaways

• Distribution Expansion: By partnering with Hims, Novo Nordisk gains access to a massive digital-native customer base, potentially increasing the volume of Wegovy and Ozempic prescriptions.

Investment Themes: Growth Stocks & GLP-1 Sector

The transcript discusses broader trends affecting growth-oriented companies and the weight loss medication sector.

• The "Broken" Growth Market: The speaker argues that the market for growth stocks has been "broken" since October 2025. Many companies have grown their revenue 10x over the last five years, yet their stock prices have remained flat (0% return over 6 years).
• GLP-1 Sensitivity: HIMS is currently trading almost exclusively on news related to GLP-1 medications. Positive clinical or partnership news is currently being overshadowed by macro-economic selling pressure.
• SoFi Technologies (SOFI): Briefly mentioned as another example of a "broken" growth stock where revenue has scaled significantly (10x) while the share price has stagnated over a five-year period.

Takeaways

• Sector Opportunity: For investors with a long-term horizon, the "dumping" of growth stocks despite strong fundamentals may represent a significant entry point, provided the investor can withstand high volatility.
• Risk Factor: The primary risk mentioned is the irrationality of the current market; even "epic" positive news is currently failing to drive share prices higher in the short term.